Get the Stockscreener App
4.78
3.63%
-0.18
After Hours:
4.87
0.09
+1.88%
Avita Medical Inc stock is traded at $4.78, with a volume of 159.52K.
It is down -3.63% in the last 24 hours and up +21.63% over the past month.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
See More
Previous Close:
$4.96
Open:
$5.04
24h Volume:
159.52K
Relative Volume:
0.71
Market Cap:
$146.42M
Revenue:
$50.14M
Net Income/Loss:
$-35.38M
P/E Ratio:
-3.4143
EPS:
-1.4
Net Cash Flow:
$-39.46M
1W Performance:
-6.46%
1M Performance:
+21.63%
6M Performance:
+12.21%
1Y Performance:
-43.90%
1-Day Range:
$4.75
$5.04
1-Week Range:
$4.75
$5.48
52-Week Range:
$3.22
$10.29
Avita Medical Inc Stock (RCEL) Company Profile
Name
Avita Medical Inc
Sector
Industry
Phone
661-568-1317
Address
28159 AVENUE STANFORD, VALENCIA, CA
Compare RCEL vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCEL
Avita Medical Inc
|
4.78 | 151.93M | 50.14M | -35.38M | -39.46M | -1.40 |
|
ABT
Abbott Laboratories
|
111.04 | 196.53B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
370.50 | 146.14B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
93.01 | 122.74B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
72.99 | 107.15B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
83.89 | 49.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Avita Medical Inc Stock (RCEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-25 | Upgrade | BTIG Research | Sell → Neutral |
| Aug-08-25 | Downgrade | BTIG Research | Neutral → Sell |
| Dec-24-24 | Initiated | D. Boral Capital | Buy |
| Apr-11-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-27-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-02-21 | Initiated | Piper Sandler | Overweight |
| Aug-27-20 | Initiated | BofA Securities | Buy |
| Apr-21-20 | Initiated | Oppenheimer | Outperform |
| Mar-03-20 | Initiated | BTIG Research | Buy |
View All
Avita Medical Inc Stock (RCEL) Latest News
Avita Medical (NASDAQ:RCEL) Now Covered by Analysts at Northland Securities - MarketBeat
Avita Medical at TD Cowen Conference: Growth and Strategic Focus By Investing.com - Investing.com Canada
RCEL SEC FilingsAvita Medical Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RCELAVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results - ADVFN Ltd
RCEL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Retail Trends: Can AVITA Medical Inc weather a recession2025 Trade Ideas & Reliable Momentum Entry Alerts - baoquankhu1.vn
Wall Street Analysts Believe Avita Medical (RCEL) Could Rally 29.87%: Here's is How to Trade - Zacks Investment Research
RCEL Stock Price, Quote & Chart | AVITA MEDICAL INC (NASDAQ:RCEL) - ChartMill
Avita Medical Inc. (NASDAQ:RCEL) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Avita Medical Targets “Progressive” 2026 Growth, Guides $80M-$85M Revenue After Headwind Year - MarketBeat
Wall Street experts predict Avita Medical (RCEL) may surge by 29.87%: Here’s how you can approach trading - Bitget
AVITA Medical to participate at the TD Cowen 46th Annual Health Care Conference - Investing News Network
Avita Medical (NASDAQ:RCEL) CFO David O'toole Purchases 3,000 Shares of Stock - MarketBeat
AVITA Medical, Inc. (NASDAQ:RCEL) Q4 2025 earnings call transcript - MSN
AVITA Medical (RCEL) CFO awarded RSU and stock option grants - Stock Titan
Avita Medical (RCEL) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Scar Treatment Market Size is Expected to Reach USD 56.30 Billion by 2033; Growth is Propelling Due to the Surging Awareness for Advanced Cosmetic and Reconstructive Procedures Globally - GlobeNewswire Inc.
RCEL: D. Boral Capital Maintains "Buy" Rating and $10 PT | RCEL Stock News - GuruFocus
Avita Medical (NASDAQ:RCEL) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Broker tips 25% upside for this ASX healthcare stock following FY25 earnings results - MSN
Earnings call transcript: Avita Medical Q4 2025 sees steady revenue growth - Investing.com Nigeria
Avita Medical Earnings Call Signals Stabilizing Growth - The Globe and Mail
Avita's Road to Profitability Is in Sight - Morningstar
AVITA Medical to Host Investor Webinar Briefing - Investing News Network
Ask AVITA Medical’s interim CEO your questions in Feb. 18 investor webinar Q&A - Stock Titan
AVITA Medical, Inc. (NASDAQ:RCEL) Q4 2025 Earnings Call Transcript - Insider Monkey
Avita Medical Q4 2025 slides: 11% annual growth with 12-19% expansion targeted for 2026 - Investing.com Canada
Earnings call transcript: Avita Medical Q4 2025 sees steady revenue growth By Investing.com - Investing.com South Africa
AVITA Medical (RCEL) Reports Strong Q4 2025 Performance - GuruFocus
Avita Medical Q4 Earnings Call Highlights - MarketBeat
AVITA Medical, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
AVITA Medical (RCEL) Q4 2025 Earnings Transcript - The Globe and Mail
RCEL Refines Financial Strategy with New Credit Facility - GuruFocus
Avita Medical (RCEL) Reports Lower Q4 Revenue Amidst Operational Transition - GuruFocus
Avita Medical earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
AVITA Medical to Announce Q4 Earnings on February 12 - Intellectia AI
Avita Medical (NASDAQ:RCEL) Issues Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
AVITA Medical, Inc. SEC 10-K Report - TradingView
AVITA Medical Q4 Earnings Summary & Key Takeaways - Benzinga
AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results - Bluefield Daily Telegraph
Lake Street raises price target on AVITA Medical, Inc. (RCEL) to $3.50, maintains hold rating - MSN
AVITA Medical Inc (AVHHL) Q4 2025 Earnings Call Highlights: Navigating Growth and Challenges By GuruFocus - Investing.com Canada
Is AVITA Medical Inc. forming a bullish divergenceEarnings Recap Summary & Fast Entry and Exit Trade Plans - mfd.ru
Bull Run: Can AVITA Medical Inc weather a recessionMarket Performance Summary & Precise Buy Zone Identification - baoquankhu1.vn
Is AVITA Medical Inc. stock a buy before product launchesTrade Risk Report & Fast Exit and Entry Trade Guides - mfd.ru
Aug Volume: What is the dividend yield of GOOSJuly 2025 EndofMonth & Verified Entry Point Signals - baoquankhu1.vn
Lake Street Raises Price Target on AVITA Medical, Inc. (RCEL) to $3.50, Maintains Hold Rating - Finviz
Avita Medical (RCEL) to Release Quarterly Earnings on Thursday - MarketBeat
Avita Medical Inc Stock (RCEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):